

iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

NCT06634628

Status	RECRUITING
Phase	Early Phase 1
Sponsor	CHDI Foundation, Inc.
Enrollment	27 participants

Key Eligibility Criteria

Inclusion (17)

- PwHD HD-ISS Stages 2 and 3 and HC participants who:
- Are female or male adults, age 18-64 years old, inclusive.
- Have body mass index (BMI) between 19 and 35, inclusive.
- Have capacity to give full informed consent in writing and have read and signed the informed consent form (ICF).
- Are able to comply with study procedures, including fasting and blood sampling.

... and 12 more (see full listing online)

Exclusion (17)

- PwHD HD-ISS Stages 2 and 3 and HC participants who:
- Are currently participating in, or are less than 30 days after completing participation in, other therapeutic or imaging studies.
- Have previously participated in a PET imaging study in the past 12 months that, cumulatively with the current study, will exceed annual regulatory limits for radiation exposure.
- Have any disease, condition, or concomitant medication that significantly compromises the function of the body systems and that, in the opinion of the Investigator, might interfere with the conduct of the study or its interpretation.
- Are pregnant and breastfeeding females.

... and 12 more (see full listing online)

Locations (1 total)

Universitaire Ziekenhuizen Leuven/ UZ Leuven/ UZL, Leuven, Belgium